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SERODIAGNOSIS UNTUK STRONGYLOIDIASIS: 
PENGENALPASTIAN KLON cDNA, PENGHASILAN ANTIGEN 
REKOMBINAN DAN PEMBANGUNAN IMUNOASAI 
 
ABSTRAK 
 
Strongyloidiasis merupakan penyakit parasit manusia yang disebabkan oleh 
cacing Strongyloides stercoralis. Jangkitan daripada cacing ini akan menyebabkan 
jangkitan jangka panjang dalam manusia, atau boleh disebarkan ke organ-organ lain, 
terutama bagi individu dengan sistem imun terkompromi, yang biasanya 
mengakibatkan kematian. Majoriti pesakit adalah tidak bersimptom, atau mengalami 
masalah gastrousus tak-spesifik, namun masih tiada kaedah ‘gold standard’ untuk 
mengesan jangkitan tersebut. Diagnosis definitif biasanya dilakukan melalui 
kombinasi tanda dan simptom klinikal, pengesanan mikroskopik, dan ujian serologi. 
Sehingga kini, ujian komersil yang sedia ada adalah berasaskan ekstrak asli antigen 
parasit, tetapi ujian tersebut mempunyai banyak kelemahan; contohnya masalah 
reaktiviti silang dengan jangkitan cacing yang lain. Ujian berasaskan antigen 
rekombinan merupakan alternatif yang sesuai bagi meningkatkan spesifisiti 
diagnostik dan keseragaman kualiti ujian, oleh itu, kajian ini dijalankan untuk 
mencapai matlamat ini. Peringkat awal kajian ini melibatkan pengujian sampel serum 
dengan in-house IgG-, IgG4- dan IgE-ELISA disamping kit komersial IgG-ELISA. 
Hasil keputusan mendapati bahawa asai IgG-ELISA menunjukkan sensitiviti yang 
tertinggi melalui kedua-dua asai in-house dan komersial (84.6%, n=26), manakala 
IgG4-ELISA menunjukkan spesifisiti yang tertinggi iaitu sebanyak 92.7% (n=55).  
Sampel serum dikategorikan mengikut kumpulan berdasarkan hasil keputusan IgG 
dan IgG4 untuk digunakan dalam eksperimen imunosaringan yang seterusnya. 
xviii 
 
Imunosaringan pertama perpustakaan faj cDNA S. stercoralis menghasilkan 
pemilihan sebanyak 20 cDNA klon bagi setiap faj imunoblot IgG- dan IgG4-. Klon-
klon ini kemudiannya digunakan dalam imunosaringan kedua dan ketiga yang 
menggunakan sampel serum terjerap individu. Akhirnya, dua klon cDNA, iaitu Ss3a 
and SsIa, telah dipilih sebagai mempunyai nilai diagnostik yang berpotensi tinggi. 
Sisipan DNA bagi Ss3a adalah sangat serupa dengan protein hipotetikal S. 
stercoralis, manakala sisipan DNA bagi SsIa adalah sama dengan protein ikatan 
immunoglobulin S. ratti. Gen Ss3a telah diekspres secara rekombinan sebagai 
protein gabungan-GST di dalam vektor pET42a dan ia disahkan melalui analisis 
MALDI TOF/TOF. Nilai diagnostik bagi protein rekombinan rSs3a ditentukan 
melalui analisis western blot dengan menggunakan sampel serum individu. 
Seterusnya, ujian dipstik aliran sisi (1 jam) telah dihasilkan dengan sensitiviti dan 
spesifisiti sebanyak 100% (n=10) and 100% (n=10). Sementara itu, gen SsIa telah 
digabungkan dengan dua label protein dalam vektor pET28b dan diekspreskan 
sebagai protein gabungan-His, dan ia disahkan melalui analisis western blot dan 
MALDI-TOF/TOF. Kemudiannya, rSs1a telah dibangunkan kepada ujian pantas 
aliran sisi (15 minit), memberikan kadar sensitiviti sebanyak 90% (n=30) dan kadar 
spesifisiti sebanyak 98% (n=46). Kajian ini telah berjaya menemukan dua penanda 
jangkitan dan menghasilkan dua protein rekombinan dengan nilai diagnostik yang 
berpotensi. Bukti konsep penggunaan kedua-dua protein tersebut dalam ujian dipstik 
aliran sisi bagi serodiagnosis penyakit strongyloidiasis telah ditunjukkan, dengan 
kombinasi kedua-duanya mungkin sesuai digunakan sebagai ujian pantas untuk 
pengesanan penyakit strongyloidiasis pada manusia.  
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SERODIAGNOSIS OF STRONGYLOIDIASIS: 
IDENTIFICATION OF cDNA CLONES, PRODUCTION OF 
RECOMBINANT ANTIGENS AND IMMUNOASSAY DEVELOPMENT 
 
ABSTRACT 
 
Strongyloidiasis is a human parasitic disease caused by the nematode 
Strongyloides stercoralis. Infection by this parasite can cause long-term infection in 
humans or can disseminate to other organs, especially in individuals with 
immunosuppression, which commonly results in fatal outcomes. The majority of 
patients are asymptomatic or present with non-specific gastrointestinal complaints, 
and there is no gold standard method to rule out the infection. Definitive diagnosis is 
usually made by a combination of clinical signs and symptoms, microscopic 
identification, and serology test. To date, the available commercial tests are based on 
native parasite antigen extract, but such tests have problems of cross-reactivity with 
other helminthic infections. A recombinant antigen-based test is a good alternative 
for improved diagnostic specificity and standardized test quality, thus, the present 
study was conducted to achieve this goal. The initial stage of the study involved 
testing serum samples with the in-house IgG-, IgG4- and IgE-ELISAs in addition to 
a commercial IgG-ELISA kit. The results showed that the IgG-ELISA assay 
demonstrated the highest sensitivity using either in-house or commercial assays 
(84.6%, n=26), whereas the IgG4-ELISA displayed the highest specificity of 92.7% 
(n=55). The serum samples were categorized into different groups based on the IgG 
and IgG4 results for use in the subsequent immunoscreening experiments. Primary 
immunoscreening of the S. stercoralis phage cDNA library resulted in the selection 
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of 20 cDNA clones from each IgG- and IgG4-phage immunoblot. These clones were 
subjected to secondary and tertiary immunoscreenings using individual pre-adsorbed 
serum samples. Finally, two cDNA clones namely Ss3a and SsIa were selected as 
having high potential diagnostic value. The Ss3a DNA insert was highly similar to a 
S. stercoralis hypothetical protein, while the SsIa DNA insert was identical to an 
immunoglobulin-binding protein of S. ratti. The Ss3a gene was recombinantly 
expressed as a GST-fusion protein in the pET42a vector and validated by MALDI 
TOF/TOF analysis. The diagnostic value of rSs3a protein was determined by western 
blot analysis using individual serum samples. Subsequently, a one-hour lateral flow 
dipstick test was produced with diagnostic sensitivity and specificity of 100%, 
respectively. Meanwhile, the SsIa gene was fused to a dual protein tag in the pET28b 
vector and expressed as a His-fusion protein and verified by western blot analysis 
and MALDI-TOF TOF. The rSs1a was then developed into a rapid (15 min) lateral 
flow dipstick test, which gave a sensitivity rate of 90% (n=30) and a specificity rate 
of 98% (n=46). This study has successfully discovered two infection markers and 
produced two new recombinant proteins of potential diagnostic value. Proof-of-
concept of their usefulness in a lateral flow dipstick test for serodiagnosis of 
strongyloidiasis was also demonstrated, and in combination may serve as a good 
rapid test for of human strongyloidiasis.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Strongyloidiasis: The overview 
Strongyloidiasis is a soil-transmitted helminthiasis capable of causing long-term 
infection as well as fatal consequences in humans. This disease is caused by two 
species of soil-transmitted helminths (STH) of the genus Strongyloides, namely, 
Strongyloides stercoralis and S. fuelleborni, with the former being the most prevalent 
species infecting humans. It is widely prevalent in populations living in tropical and 
sub-tropical climates, affecting approximately 100-370 million people worldwide 
(Bisoffi et al., 2013).  
The World Health Organization (WHO) has listed 17 diseases as neglected 
tropical diseases (NTDs). Seven of them are parasitic diseases, namely, cysticercosis, 
dracunculiasis, echinococcosis, foodborne trematodiases, lymphatic filariasis, 
onchocerciasis, schistosomiasis, and soil-transmitted helminthiases 
(http://www.who.int/neglected_diseases/diseases/en/). These diseases were grouped 
as NTDs because they have been largely wiped out in the more developed parts of 
the world and persist only in the poorest, most marginalized communities and 
conflict areas; where they cause tremendous suffering due to their disfiguring, 
debilitating, and sometimes fatal impact (http://www.cdc.gov/globalhealth/ntd/).  
Among the STH, attention has historically been focused on four species, 
namely, Ascaris lumbricoides, Trichuris trichiura, and hookworms (Ancylostoma 
duodenale and Necator americanus) (Krolewiecki et al., 2013). Infection by S. 
stercoralis has received less attention and often overlooked because of the major 
challenges presented in measuring the infection and the complex diagnostic methods. 
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Therefore, strongyloidiasis is mostly known as “the most neglected of the neglected 
tropical diseases” (Olsen et al., 2009).  
Although the need for research to improve the diagnosis of strongyloidiasis had 
been highlighted over three decades ago, there is still no definitive or “gold standard” 
method to rule out the infection. This is the reason for the undetected persistence of 
the parasite inside the human body over decades, with the current record of chronic 
infection for 75 years (Prendki et al., 2011).  
The clinical manifestations of the disease ranges from asymptomatic light 
infection to chronic symptomatic infection, or it may progress to life-threatening 
dissemination of larvae to all internal organs among individuals with compromised 
immune system (Olsen et al., 2009). It was reported that strongyloidiasis was 
accountable for a mortality rate of about 60-85% amongst immunocompromised 
patients (Ericsson et al., 2001) and contributed to 16.7% of the mortality rate for 
patients requiring hospitalization (Iriemenam et al., 2010). 
Cases of patients infected with strongyloidiasis have recently increased due to 
the increasing numbers of transplant recipients and patients with altered immune 
status, malignancies and malnutrition. These complications are highly associated 
with the immunosuppression caused by corticosteroids and infection with human T 
lymphotropic virus type 1 (HTLV-1), the two most common risk factors for 
strongyloidiasis; however, the greatest risk is visiting an endemic area (Mirdha, 
2010).  
As strongyloidiasis contributes to serious outcomes in certain groups of 
populations, misdiagnosis and untreated infections could lead to fatality, prompting 
serious problems in the community. Therefore, understanding the nature, 
epidemiology, and immunological factors of S. stercoralis as well as the overall 
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aspect of strongyloidiasis may lead to better prevention, diagnosis, and treatment of 
the disease. 
 
1.2 History of the discovery of S. stercoralis 
S. stercoralis was first described back in July 1876 by Louis Normand, a military 
physician from France. He discovered a novel worm in the faeces of soldiers 
returning from World War II and the Cochin-China (Vietnam) war who were 
suffering from diarrhoea. The worm was then named Anguillula stercoralis by his 
colleague, Bavay, to reflect its shape (Latin: “anguillula” = “eel” and “stercus” = 
“dung”). Bavay was also the first to describe the free-living adults parasite he found 
in vitro (Grove, 1995).  
Then, in 1878, Grassi and Parona from Italy reviewed the findings of this 
parasite and renamed it Strongyloides intestinalis (Greek: “Strongylos” = “round” 
and “Eidos” = “similar”). However, in 1881, the name of this parasite was once again 
changed by Perroncito, who called it Pseudorhabditis stercoralis, as he found and 
cultivated free-living adult worms from larvae identical to the A. stercoralis. Two 
years later, Leuckart realized that all of these worms were the same but from 
different phases in the life cycle of a single parasite. He then suggested the name 
“Rhabdonema strongyloides”. After several names had been suggested and changed, 
finally, in 1902, Stiles and Hassall pointed out that the correct name of this parasite 
should be Strongyloides stercoralis, and this name was accepted by the International 
Commission on Zoological Nomenclature in 1915 (Lindo and Lee, 2002).   
The migratory route of this parasite inside the host was first studied by 
Fulleborn in 1914 (Cox, 2002). It was not until the 1930s, 50 years after its first 
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discovery that the full life cycle, pathology, and clinical features of S. stercoralis in 
humans were fully disclosed (Schär et al., 2013). 
 
1.3 The organism S. stercoralis 
1.3.1 Taxonomy 
The species S. stercoralis is classified under the genus Strongyloides, family of 
Strongyloididae, order Rhabditida, class Secernentea, and phylum Nematoda. In the 
United States, this genus is commonly known as threadworm, and it is called 
pinworm in the United Kingdom (Liu, 2012). There are more than 52 species of the 
genus Strongyloides; however, only two species are known to parasitize humans, 
namely S. stercoralis and S. fuelleborni, with the former the most pathogenic species 
in humans and causes majority of the infections. Other than humans, dogs and 
primates are also susceptible to infection with S. stercoralis (Bonne-Année et al., 
2011).  
S. fuelleborni is a zoonosis that usually occurs in non-human primates, and the 
main source of infection is monkey faeces. There are two subspecies of S. 
fuelleborni, namely S.f. fuelleborni and S.f. kellyi, which are reported to cause 
infection in humans in Africa and Papua New Guinea respectively (Cox, 2002). 
According to King and Mascie-Taylor (2004), S.f. kellyi is responsible for 27% of 
Strongyloides infections amongst children, with 81% of them being under 12 months 
old. It caused a potentially fatal disease among children called ‘swollen belly 
syndrome’ (SBS). The high percentage of incidence among young children might be 
due to the habits of the mothers, who carry their children in string bags lined with 
dried banana leaves and/or cloth. These materials are changed infrequently, and eggs 
and free-living larvae have been found (Brooker and Bundy, 2009).  
5 
 
The difficulty in maintaining S. stercoralis in the respective host limits the 
investigation into this organism; therefore, S. ratti and S. venezuelensis, which 
naturally infect rodents, have been used to study the biology and immunology of 
Strongyloides infection (Bonne-Année et al., 2011). Some limitations have been 
encountered with such studies, as the results generated with rodent parasites do not 
mimic the actual pathogenesis of the human pathogen S. stercoralis. They migrate 
throughout the body; therefore the recovery of the parasites is problematic, and study 
of the microenvironment of the host is nearly impossible (Bonne-Année et al., 2011).  
 
1.3.2 Morphology 
S. stercoralis has two different life cycles, namely, the parasitic and the free-living 
life cycles. The morphology of the parasite in the former is different from in the 
latter. Figure 1.1 shows the difference in the morphology of adult S. stercoralis 
larvae between the two life cycles, i.e. parasitic female, free-living male and free-
living female.  
 The parasitic female of S. stercoralis is approximately 2.0-2.8 mm in length, 
has an average diameter of 37 µm, and a blunt-ended tail. It is very slender and 
threadlike, giving rise to the common name, ‘threadworm’ (Lindo and Lee, 2001). 
As described by Grove (1995), the body of the female worm is attenuated anteriorly, 
and it contains a long cylindrical oesophagus (also called the pharynx). The 
oesophagus is followed by the intestine and is surrounded by a nerve ring. The vulva 
is located in the mid-ventral line in the posterior third of the body (Grove, 1995). 
Parasitic worms are parthenogenetic females; their reproductive organs develop after 
the male reproductive organs have disappeared. There is no parasitic male (Simon, 
2009).  
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 The length of the free-living adult female is shorter, ranging from 0.9-1.7 mm, 
but the diameter is about 85 µm. It has a thin cuticle and is transparent, and the 
oesophagus is attached to the terminal mouth. The reproductive system is similar to 
that seen in the parasitic female except that each uterus contains numerous eggs 
(Grove, 1995). However, using a dissecting microscope, the free living adult female 
is easily seen in cultures, while the parasitic female is barely visible in stool samples, 
except in a very severe infection (Lindo and Lee, 2001). This is because the parasitic 
females lie embedded within the mucosal epithelium of the proximal small intestine 
where they deposit their eggs (Simon, 2009).  
The free living male of S. stercoralis is approximately 1.0-1.2 mm long and 55 
µm in diameter and has a typical J shape with a sharply pointed tail (Lindo and Lee, 
2001). The mouth, oesophagus, and intestine are similar to those seen in the free-
living female. The reproductive system consists of a blindly ending testis at the 
anterior end, and it is attached to a poorly demarcated vas deferens and seminal 
vesicle (Lindo and Lee, 2001). 
 The eggs of parasitic and free-living females are morphologically similar, with 
a thin-shelled, ellipsoidal shape, and measure between 40 x 70 µm in size (Grove, 
1995). The eggs may be fully embryonated when laid or may have undergone several 
cell divisions (Lindo and Lee, 2001). The eggs hatch within the submucosa or during 
passage through the lumen of the intestine, liberating rhabditiform larvae, which are 
then excreted with the faeces (Nappi and Vass, 2002). 
 
 
 
 
  
 
 
 
http://rowdy.msudenver.edu/~churchcy/BIO3270/Images/Nematodes/Strongyloides_stercoralis.htm
Figure 1.1 The morphology of a) parasitic female, b) free
living female of S. stercoralis
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1.3.3 Life cycle 
The life cycle of S. stercoralis is unique, with its alternation between free-living and 
parasitic cycles enabling the worms to live in the environment and in the human host. 
Additionally, this parasite has the potential for autoinfection and multiplication 
within the host, making it different from any other nematode. Two types of life 
cycles exist, that is, an external sexual cycle involving free-living worms in the 
environment and an internal asexual cycle involving parasitic worms in the host. 
Therefore, reproduction takes place at two different sites. Figure 1.2 depicts a 
summary of its life cycle. 
Infection is initiated when a free-living third-stage infective larva (L3) 
penetrate the skin of the human host. There is then a period of larval migration 
within the host, during which the L3 larvae undergo rapid development from the 
free-living third-stage larvae to a post-penetration, host-adapted transformed stage 
called the L3+ (Bonne-Année et al., 2011; Brigandi et al., 1998; Brigandi et al., 
1997). The L3+ differs antigenically as well as physiologically from the L3 due to the 
different environments where the two forms of larvae reside, as reported by 
Maruyama et al. (2006) (Bonne-Année et al., 2011). Females are the only adult 
worms to form the parasitic stages of Strongyloides, as the male disappears from the 
bowel soon after oviposition (Viney and Lok, 2007).  
Inside the host, eggs are produced by the female worms parthenogenetically, 
that is, via asexual reproduction without the presence of the adult male worm 
(Brooker and Bundy, 2009). The female worms deposit their eggs in the mucosal 
epithelium of the small intestine. The eggs then hatch to become rhabditiform larvae 
or are passed in the stool, and so enter the free-living cycle, which is sometimes 
called the external parasitic, indirect, or sexual cycle. Thus, the presence of 
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rhabditiform in the stool sample is considered as diagnostic of strongyloidiasis, since 
the eggs are rarely found (Lindo and Lee, 2001) 
Inside the host’s gut, the rhabditiform L1 emerge from the eggs and moult 
twice to become infective L3 larvae while they are still in the intestinal lumen of the 
host. The infective filariform larvae then penetrate either the intestinal mucosa, 
causing internal autoinfection, or the skin of the perianal area, causing external 
autoinfection (http://www.cdc.gov/parasites/strongyloides/biology.html). This cycle 
continues, with the female adult larvae producing eggs parthenogenetically 25-30 
days after initially penetrating the skin (Liu, 2012). The ability of autoinfection to 
initiate a new life cycle allows the persistence of the infection for decades.  
In the free-living stage, the rhabditiform larvae undergo further development in 
the soil, moulting directly to become infective filariform larvae via the homogonic 
cycle (Nappi and Vass, 2002). Alternatively, when the environmental conditions are 
optimal, rhabditiform larvae develop into free-living male and female adult worms 
that mate and produce eggs; the eggs hatch to release L1 larvae, moult again to 
become L2, and then again to become the infective filariform L3 stage through the 
heterogonic cycle (Grove, 1995). The infective L3 stages produced by these two 
cycles are long lived, and they can persist in the environment until they encounter a 
suitable host, continuing the life cycle following skin penetration (Viney and Lok, 
2007).  
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http://www.cdc.gov/dpdx/strongyloidiasis/index.html 
 
 
Figure 1.2 The life cycle of S. stercoralis 
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Heterogenic cycle 
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1.3.3.1 Autoinfection 
Autoinfection is defined as the ability to replicate and multiply within the same host 
in the absence of external sources of infection (Gillespie and Pearson, 2001). In the 
Strongyloides genus, S. felis was found to have this trait as well as S. stercoralis 
(Speare and Durrheim, 2004). As mentioned previously, autoinfection may arise in 
one of two ways: i) the filariform larvae penetrate and lodge in the intestinal mucosa 
(internal autoinfection), or ii) the filariform larvae re-invade the bowel or perianal 
skin (external autoinfection) (Liu, 2012; Brooker and Bundy, 2009). The capability 
to establish a new cycle of repeated endogenous infection in the human host means 
the infection can persist for up to 75 years in immunocompetent individuals (Prendki 
et al., 2011). In immunocompromised individuals, it can lead to possible 
multiplication causing a tremendous increase in the worm burden, which in turn, 
leads to hyperinfection or disseminated syndrome (Liu, 2012).  
 
1.4 Epidemiology 
Strongyloidiasis is endemic worldwide; it can be found in countries with hot and 
humid climates but predominantly in resource-poor countries with inadequate 
sanitary conditions. The current prevalence of strongyloidiasis is estimated to be 
around 100-300 million cases (Taylor et al., 2014). This prevalence varies 
substantially between countries and continents due to ecological, socio-cultural, and 
economic factors, in addition to the type of diagnostic method and the number of 
studies undertaken. A review study conducted by Schär et al. (2013) reported a 
countrywide prevalence of strongyloidiasis based on three different subsets: 
community-based studies, hospital-based studies, and studies on refugees and 
immigrants.   
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Community-based studies have revealed that Brazil and Thailand are endemic 
countries for strongyloidiasis, and these two countries possess reliable and consistent 
data on the infection, with the proportion of the infection reported as being 13% and 
23.7% respectively (Schär et al., 2013). One of the biggest community-based studies 
was conducted in Africa, and involved screening 20,250 individuals across 216 
villages; the study revealed an infection rate of 11.6% among the community (Schär 
et al., 2013; Yelifari et al., 2005). Meanwhile in Japan, strongyloidiasis was found in 
older persons, with sustained infection, probably due to auto-infection, contributing 
to an overall infection rate of 16.4% in an endemic area of Okinawa prefecture 
(Arakaki et al., 1992).  In a study conducted by Steinmann et al. (2007), the reported 
prevalence of strongyloidiasis in China was 11.7%, in which the endemic areas were 
found to be mostly farming communities. Based on the results of five prevalence 
studies, the reported prevalence of strongyloidiasis in Australia was found to be in 
the range of 0% to 60%, with screening taking place among the aboriginal 
communities in northern Australia (Johnston et al., 2005).  
A hospital-based study analysing 37,621 laboratory specimens over a period of 
two years in the Campinas City region in Brazil demonstrated an overall prevalence 
rate of 10.8% (Rossi et al., 1992), while a prevalence rate of 11.2% in India was 
obtained from nine hospital-based prevalence studies, five of which focused on the 
screening of HIV/AIDS patients (Schär et al., 2013).  
In the US, 347 deaths related to strongyloidiasis were reported from 1991 to 
2006; this figure is equivalent to 14-29 deaths per year (Croker et al., 2010). The 
prevalence studies in Americas were well covered; two thirds of the epidemiologic 
studies in America focused mainly on refugees and immigrants. Similarly, 
seroprevalence studies in European countries focused on refugees, immigrants, and 
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travellers . In the United Kingdom, it is believed that S. stercoralis infection might 
have persisted over a long period, since many of the infections were identified 
among World War II veterans who had not left the country in the 60 years following 
their return from deployment in Southeast Asia (Schär et al., 2013). The reported 
prevalence in the UK was 12% (Gill et al., 2004). In Canada, a strongyloidiasis 
prevalence rate of 11.8% was reported among Vietnamese refugees, and 76.6% 
among Cambodian refugees (Gyorkos et al., 1990). Screening of 5,518 female 
housekeepers from different Asian countries working in Saudi Arabia revealed an 
overall prevalence of 0.6%, of which 0.4% were Filipinos, 0.5% Indonesians, 1.5% 
Sri Lankans, 2.6% Indians and 3.4% Thais (Madani and Mahfouz, 1995). 
South-East Asia (SEA) possesses climatic, ecological, and socio-economic 
conditions that favour the transmission of S. stercoralis. Yet, information on the 
occurrence of strongyloidiasis from these countries is relatively scarce. In a 
systematic literature review of all peer-reviewed research articles published over the 
last 25 years conducted by Schär et al. (2015), they reported that the prevalence of S. 
stercoralis in Thailand ranged from 0.1% to as high as 38.8% when the infection was 
screened for among the general population, i.e. villagers and school-children. 
Thailand had by far the most extensive studies on the prevalence of strongyloidiasis 
among any other SEA countries. Meanwhile, a cross-sectional study carried out by 
Khieu et al. (2014) in rural Cambodia revealed that strongyloidiasis is highly 
prevalent among the general Cambodian population, with a prevalence rate of 44.7%. 
It is likely that the examination of multiple stool samples, the range of diagnostic 
methods employed, and poor sanitary conditions are the main factors that contributed 
to the high prevalence rate reported in this area. Similar reasons were also likely to 
be the main cause of the high prevalence rate of strongyloidiasis (41%) reported in 
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Lao PDR (Vonghachack et al., 2015). Seven screening studies conducted in 
Indonesia, covering the areas of Flores Island, Bali, and Irian Jaya Island, reported a 
prevalence rate lower than 1.0% to 1.6% (Schär et al., 2015). This low reported 
prevalence is believed to be due to the use of not highly sensitive diagnostic method 
(i.e. Harada-Mori technique) and the limited presence of S. stercoralis larvae. 
Meanwhile, no S. stercoralis infection was found in a study conducted in Vietnam. 
However, since the prevalence of hookworm infection was reported to be 28.6%, it is 
believed that strongyloidiasis is probably also present in Vietnam (Hung et al., 
2005). No published report could be found on the prevalence rate of strongyloidiasis 
in Singapore, Brunei, Myanmar, and the Philippines (Schär et al., 2015).  
 In Malaysia, the first review case of a patient with gastric strongyloidiasis was 
histologically documented by Shekhar et al. (1997).  Kuze et al. (2010) published a 
paper on the discovery of the rhabditoid larvae of Strongyloides sp. and S. 
fuellerborni from the faeces of orang utans in Sabah. Studies on the prevalence of S. 
stercoralis infection in this country is very limited; only four studies were conducted 
from 1997 to 2013, two of which studied the minority community of Orang Asli in 
rural areas and the rest were hospital-based studies in Sarawak and Kelantan. 
Rahmah et al. (1997) reported a low prevalence (1.2%) of strongyloidiasis among the 
Orang Asli minority community in Kelantan. In the same minority community, 
Ahmad et al. (2013) found no S. stercoralis larvae in 54 coprologically analyzed 
stool samples; however, serological examination of the corresponding serum samples 
revealed a prevalence of 31.5%. In a hospital-based study among patients with 
gastrointestinal symptoms in an endemic area of STH Sarawak, Basuni et al. (2011) 
reported a prevalence of strongyloidiasis to be 39.0% using pentaplex-PCR. 
Investigation of S. stercoralis infection among cancer patients in a major hospital in 
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Kelantan using several detection methods by Zeuter et al. (2014) revealed a 
seroprevalence of 3.1% when measured by IgG4-ELISA, 0.5% by microscopy and 
1.6% by real-time PCR.  
 Figure 1.3 shows the prevalence of strongyloidiasis worldwide. It is noted that 
the high prevalence rates of Strongyloides infection were noted in areas where 
rigorous diagnostic approaches were engaged in the studies, be it due to multiple 
diagnostic methods or the large numbers of samples examined. In contrast, the low 
prevalence reported in certain areas might be due solely to the low sensitivity of the 
diagnostic method employed. This suggests that the prevalence of strongyloidiasis 
worldwide might be underestimated, as research into prevalence is highly dependent 
on the factors mentioned above. Therefore, a more sensitive and specific diagnostic 
method is required for an accurate measurement of prevalence as well as mapping 
the endemicity of the infection.  
 
  
  Figure 1.3 Worldwide prevalence of strongyloidiasis 
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1.5 Transmission of the infection 
1.5.1 Horizontal transmission 
Humans are generally infected by S. stercoralis transcutaneously when the infectious 
filariform larvae in faecally contaminated soil enter the skin or mucous membranes 
during agricultural, recreational, or domestic activities (Ramanathan and Nutman, 
2008). There are also cases of infection induced by the oral administration of water 
contaminated with filariform larvae (Keiser and Nutman, 2004) or the ingestion of 
contaminated food (Wirk and Wingard, 2009). Human-to-human transmission is 
uncommon; however, such transmission has been described among homosexual men 
(Simon, 2009). A group of cases were also reported in institutionalized individuals 
with mental retardation, suggesting that nosocomial transmission could possibly 
occur (Keiser and Nutman, 2004). 
 
1.5.1.1 Soil transmission 
Humans are prone to S. stercoralis infection when the person is exposed to 
contaminated soil harbouring infective filariform larvae. Thus, visiting an endemic 
area becomes the largest risk factor for acquiring S. stercoralis infection. Two cases 
of acute strongyloidiasis infection were reported in Italian tourists after visiting 
beaches in Koh Samui Island, Thailand (Angheben et al., 2011). Meanwhile, bathing 
in the rivers and consuming non-drinking water has been shown to have a significant 
association with strongyloidiasis (Herrera et al., 2005). Farmers and coal miners are 
the two occupations with the highest risk of getting the infection, while children are 
prone to this disease due to their behaviours, which favour the transmission of the 
soil-based helminths – dirty hands, mouth contact, and going bare foot when playing 
on contaminated ground (Liu, 2012).   
18 
 
1.5.1.2 Oral route of transmission 
The Strongyloides larvae have been found contaminating local vegetation, by which 
the infection can be transmitted orally to humans. Some people especially 
Kelantanese have the custom of eating raw vegetables and herbs, i.e. daun kesum 
(Vietnamese mint), pegaga (Centella asiatica), and water spinach (Ipomoea 
aquatic); these plants are collectively known as ulam (Zeehaida et al., 2011). Most of 
these ulam grow in areas near the drains, a place that favours the growth of the 
parasite. Zeehaida et al. (2011) revealed the presence of live rhabditiform S. 
stercoralis larvae in the water samples used to wash these vegetables, highlighting 
the possibility of oral route transmission to the public, vegetables sellers and food 
handlers.  
 
1.5.1.3 Person to person transmission 
The possibility of the transmission of larvae from one person to another via direct 
contact is low; hence, few reports are available. In 1982, Grove conducted a survey 
investigating the possible transmission of S. stercoralis from 24 men who had been 
infected with strongyloidiasis for many years to their spouse. The results showed that 
none of the wives were infected, suggesting that the risk of transmission is small. 
Indeed, no evidence of transmission was found in medical staff in charge of patients 
with disseminated strongyloidiasis (Sugiyama et al., 2006; Maraha et al., 2001). 
However, the risk of infection could still be present if safety precautions are not 
strictly followed. For instance, Czachor and Jonas (2000) reported a case of S. 
stercoralis infection in an 84-year old wife who had routinely provided personal care 
and attended to the secretions of her ill husband, who had hyperinfestation syndrome. 
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The wife presented with uncharacterized symptoms two weeks after her husband’s 
death.  
The likelihood of transmission among homosexuals is greater (Grove, 1982). 
A case was reported by Sorvillo et al. (1983) who identified the presence of S. 
stercoralis in the faeces of a homosexual patient and his contacts. Thus the risk of 
person-to-person transmission among homosexuals should not be ignored. 
 
1.5.2 Vertical transmission 
The occurrence of vertical transmission of strongyloidiasis in humans is unknown. In 
a study conducted by Shoop et al. (2009), they examined the possibility of the 
vertical transmission of S. stercoralis in three female dogs at a different stages of the 
reproductive cycle (preconception, gestation, and postpartum) which were injected 
with S. stercoralis filariform larvae. None of the pups born to females infected before 
conception and during gestation harboured the larvae, thus showing that transmission 
through prenatal pathways does not occur. However, live filariform larvae of S. 
stercoralis were found in milk samples taken from lactating female dogs, suggesting 
that transmission of the parasite through transmammary route. The larvae are able to 
become dormant in the tissue, and this was found to be the key for transmammary 
transmission. The infective L3 presumably arrest their development and migration in 
the mammary glands, and then reactivate at lactation (Liu, 2012).  
Recently, a single case of a pregnant woman who died due to strongyloidiasis 
has been reported by Buresch et al. (2015). The woman, who was at week 25 of 
gestation, was given a corticosteroid to resolve the acute abdominal pain and 
abnormal foetal heart tracing. Unfortunately, she developed septic shock, due to 
hyperinfection causing stillbirth to occur, and finally she succumbed to the disease.  
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1.6 Clinical manifestation of strongyloidiasis 
1.6.1 Acute 
The primary infection with S. stercoralis is initiated by penetration of the infective 
filariform larvae through the intact skin. This early stage of infection is usually 
asymptomatic, or it may manifest as mild larva currens, an allergic reaction due to 
migration of the filariform larvae (Mahmoud, 1996). The migration can progress as 
quickly as 10 cm/hr (Satoskar et al., 2009). Slight haemorrhage, swelling, and itching 
are sometimes noted at the site of larva entry; these symptoms can occur almost 
immediately and can last for several weeks (Keiser and Nutman, 2004; Freedman, 
1991).  
After penetrating the skin, the infective filariform larvae enter the blood, and 
they are then transported to the lungs via the pulmonary circulation. At this time, 
patients usually suffer from symptoms that resemble Loffler’s syndrome, such as 
coughing, shortness of breath, wheezing, and transient pulmonary filtrates 
(Mahmoud, 1996). Inside the lungs, the larvae penetrate the alveoli and migrate 
upwards to the tracheobronchial tree; they are then swallowed entering the gut, 
where they complete their maturation. These larvae will then moult to become adult 
female worms and lodge in the submucosal tissues inside the proximal small 
intestine (Simon, 2009). At this stage, abdominal symptoms and signs such as 
indigestion, cramping abdominal pain, and diarrhoea with malabsorption and weight 
loss, have been commonly observed (Mahmoud, 1996) about two weeks after 
infection, with the larvae detectable in the stool after three to four weeks (Keiser and 
Nutman, 2004). All of these may be misdiagnosed as being due to irritable bowel 
syndrome (Grove, 1995).  
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1.6.2 Chronic 
Unresolved acute infection can lead to the development of chronic infection, causing 
a variety of manifestations, most commonly infections to the skin and 
gastrointestinal system (Grove, 1995). Meanwhile, chronic infection, without prompt 
diagnosis and proper treatment can lead to severe complicated strongyloidiasis 
characterized by a wide range of complicated forms of disease, including 
gastrointestinal, pulmonary, and neurological complications and other presentations 
such as urinary tract infections and pelvic inflammation (Grove, 1995). The major 
target areas are the bowel, lungs, and central nervous system. Usually, this leads to 
presence of secondary bacterial infection, which increases the risk of mortality in 
patients not only due to the hyperinfection syndrome, but also due to the underlying 
condition which predisposes to dissemination (Grove, 1995).   
Autoinfection is the main reason for the persistence of this organism in the host 
for decades. A more severe form of autoinfection is the hyperinfection syndrome 
(HS). The hallmark of HS is an increase in the number of larvae found in the stool 
and/or sputum along with a clinical manifestation that is confined to the usual 
migratory pathway of the parasite, i.e. the respiratory and gastrointestinal systems 
and the peritoneum (Liu, 2012). Patients with HS at the gastrointestinal sites usually 
suffer from clinical manifestations, such as cramping abdominal pain, watery 
diarrhoea, nausea, vomiting, gastrointestinal bleeding, and weight loss. Meanwhile, 
hyperinfection in the extraintestinal sites include coughing, wheezing, and 
pulmonary haemorrhaging with diffuse bilateral infiltrates seen on the chest x-rays 
(Liu, 2012).  
The key factors contributing to HS are drug-induced or concurrent 
immunosuppressive conditions, such as solid tumours, corticosteroid use, HTLV-1 
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and HIV infection, or Hodgkin’s lymphoma (Gillespie and Pearson, 2001). HS 
occurs in 1.5-2.5% of patients with strongyloidiasis, contributing to a 15% mortality 
rate among HS patients, which increases to 87% when there is dissemination 
(Marcos et al., 2008; Vadlamudi et al., 2006). 
The uncontrolled HS may result in the dissemination and massive migration of 
the infective larvae outside the usual migration pattern to the other extraintestinal 
organs; this usually leads to a fatal outcome. The larvae are found in other organs, 
including the liver, the kidneys, and the central nervous system (Simon, 2009). 
During the migration, the larvae facilitate the translocation of intestinal bacteria, such 
as Streptococcus bovis, Escherichia coli, Streptococcus fecalis, Klebsiella 
pneumonia, or Enterobacter sp. to other locations of the body (Liu, 2012). These gut 
flora invade the host tissues either through the penetration of infective larvae from 
the bowel lumen or through the damaged intestinal epithelium causing concomitant 
secondary disease, such as septicaemia, meningitis, liver abscess, and pancreatitis 
(Mahmoud, 1996). Cases of disseminated strongyloidiasis have been reported to be 
associated with systemic erythematosus (SLE) (Setoyama et al., 1997), nephrotic 
syndrome (Morimoto et al., 2002), and malignant tumours (Genta et al., 1989).  
 
1.7 Strongyloidiasis in patients with associated problems 
1.7.1 Immunosuppressed patients 
Immunosuppressed patients are among the populations most at risk of developing the 
life-threatening clinical syndromes associated with strongyloidiasis, i.e. HS or 
dissemination (Marcos et al., 2011). These patients include those with human T-cell 
lymphotrophic virus type I (HTLV-I) infection, patients with hematologic 
malignancies, and patients who have received systemic corticosteroids or an 
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allogeneic hematopoietic stem cell transplantation (HSCT) (Marcos et al., 2008). 
Indeed, leukaemia and lymphoma account for up to 90% of the cases of malignancy-
associated severe strongyloidiasis (Schaffel et al., 2001; Igra-Siegman et al., 1981). 
In the US, the overall frequency of infection amongst 322,593 cancer patients 
diagnosed between 1971 and 2003 was found to be 0.8 per 10,000 patients and to be 
2.0 per 10,000 among patients with leukaemia (Safdar et al., 2004). Meanwhile, in 
Malaysia, S. stercoralis infection was detected in 4.2% of cancer patients, thus 
highlighting the high association of strongyloidiasis among immunosuppressed 
cancer patients (Zueter et al., 2014).  
In general, immunosuppression develops one to three weeks after the 
administration of the immunosuppressant (Thackery, 2002), and signs and symptoms 
of strongyloidiasis are seen in immunosuppressed patients as early as 20 days and as 
late as several years after the onset of steroid therapy (Keiser and Nutman, 2004). In 
a high-dose corticosteroid treatment, it can take less than ten days to transform a 
previously clinically silent undetected infection into overwhelming dissemination 
(Genta, 1992). Patients of these cases mostly received glucocorticoids (one of the 
corticosteroids), which is the most widely used treatment and the most specifically 
associated with transforming chronic strongyloidiasis to hyperinfection (Keiser and 
Nutman, 2004).  
The link between corticosteroid therapy and strongyloidiasis has been widely 
reviewed. According to Corrigan (1999), the corticosteroids have the effect of 
reducing the levels of circulating eosinophils by inhibiting their proliferation and 
increasing apoptosis, in addition to inducing cell death in immature lymphocytes 
(Marcos et al., 2008). It was also been hypothesized that corticosteroids may directly 
affect the female worms, accelerating the transformation of rhabditiform to invasive 
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filariform larvae (Genta, 1992), or rejuvenating reproductively latent adult females 
(Keiser and Nutman, 2004; Mansfield et al., 1996).  
The use of other immunosuppressants other than corticosteroids has also been 
associated with a number of cases of hyperinfection, i.e. vinca alkaloids (Jamil and 
Hilton, 1992), cyclosporine (Palau and Pankey, 1997), azathioprine (Weller et al., 
1981), and VP16 (Tabacof et al., 1991). 
 
1.7.2 Association with solid organ transplantation 
More than one-half of cancer patients who had strongyloidiasis also had an 
underlying solid-organ malignancy (Safdar et al., 2004). Post-transplantation tropical 
infection is a major risk in the organ recipient, which is frequently misdiagnosed by 
clinicians. It is thought that most Strongyloides infections in organ transplant 
recipients are caused by the reactivation of chronic infection after the initiation of 
immunosuppressive therapy or donor-derived infection.  
The incidence of Strongyloides infection post-transplantation in organ 
recipients is increasing annually due to the increase in international travel and the 
rising number of transplant procedures taking place in tropical countries. The most 
frequent occurrence of Strongyloides infection was found in renal transplantation 
(Marcos et al., 2008), with one of the earliest cases described in 1971 (Snydman et 
al., 2009; Fagundes et al., 1971). Other cases of strongyloidiasis have also been 
reported in recipients of intestinal transplant (Patel et al., 2008), liver transplant 
(Rodriguez et al., 2009), heart transplants (Ziad El Masry and O’Donnell, 2005) and 
lung transplants (Balagopal et al., 2009). Two cases of symptomatic chronic 
strongyloidiasis in immunosuppressed children following treatment for solid organ 
malignancies were reported in Malaysia by Norsarwany et al. (2012).   
